Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model.

Veldman MB, Rios-Galdamez Y, Lu XH, Gu X, Qin W, Li S, Yang XW, Lin S.

Mol Neurodegener. 2015 Dec 9;10:67. doi: 10.1186/s13024-015-0063-2.

2.

The choreography of neuroinflammation in Huntington's disease.

Crotti A, Glass CK.

Trends Immunol. 2015 Jun;36(6):364-73. doi: 10.1016/j.it.2015.04.007. Epub 2015 May 20. Review.

3.

Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.

Indersmitten T, Tran CH, Cepeda C, Levine MS.

J Neurophysiol. 2015 Apr 1;113(7):2953-66. doi: 10.1152/jn.01056.2014. Epub 2015 Feb 11.

4.

Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.

Tsika E, Kannan M, Foo CS, Dikeman D, Glauser L, Gellhaar S, Galter D, Knott GW, Dawson TM, Dawson VL, Moore DJ.

Neurobiol Dis. 2014 Nov;71:345-58. doi: 10.1016/j.nbd.2014.08.027. Epub 2014 Aug 29.

5.

Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits.

McKinstry SU, Karadeniz YB, Worthington AK, Hayrapetyan VY, Ozlu MI, Serafin-Molina K, Risher WC, Ustunkaya T, Dragatsis I, Zeitlin S, Yin HH, Eroglu C.

J Neurosci. 2014 Jul 9;34(28):9455-72. doi: 10.1523/JNEUROSCI.4699-13.2014.

6.

The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Chopra R, Shakkottai VG.

Neurotherapeutics. 2014 Oct;11(4):751-63. doi: 10.1007/s13311-014-0289-7. Review.

7.

Caenorhabditis elegans as a model system for studying non-cell-autonomous mechanisms in protein-misfolding diseases.

Nussbaum-Krammer CI, Morimoto RI.

Dis Model Mech. 2014 Jan;7(1):31-9. doi: 10.1242/dmm.013011. Review.

8.

Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease.

Wan J, Savas JN, Roth AF, Sanders SS, Singaraja RR, Hayden MR, Yates JR 3rd, Davis NG.

Chem Biol. 2013 Nov 21;20(11):1421-34. doi: 10.1016/j.chembiol.2013.09.018. Epub 2013 Nov 7.

9.

Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.

Lee CY, Cantle JP, Yang XW.

FEBS J. 2013 Sep;280(18):4382-94. doi: 10.1111/febs.12418. Epub 2013 Jul 31. Review.

10.

Huntington's disease: the past, present, and future search for disease modifiers.

Clabough EB.

Yale J Biol Med. 2013 Jun 13;86(2):217-33. Print 2013 Jun. Review.

11.

Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model.

Lee W, Reyes RC, Gottipati MK, Lewis K, Lesort M, Parpura V, Gray M.

Neurobiol Dis. 2013 Oct;58:192-9. doi: 10.1016/j.nbd.2013.06.002. Epub 2013 Jun 10.

12.

Role of cerebral cortex in the neuropathology of Huntington's disease.

Estrada-Sánchez AM, Rebec GV.

Front Neural Circuits. 2013 Feb 18;7:19. doi: 10.3389/fncir.2013.00019. eCollection 2013. Review.

13.

Aging of the NMDA receptor: from a mouse's point of view.

Magnusson KR.

Future Neurol. 2012 Sep;7(5):627-637.

14.

Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.

Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S, Tabrizi SJ, Stella N, Muchowski PJ.

J Neurosci. 2012 Dec 12;32(50):18259-68. doi: 10.1523/JNEUROSCI.4008-12.2012.

15.

Mouse models of polyglutamine diseases: review and data table. Part I.

Figiel M, Szlachcic WJ, Switonski PM, Gabka A, Krzyzosiak WJ.

Mol Neurobiol. 2012 Oct;46(2):393-429. doi: 10.1007/s12035-012-8315-4. Epub 2012 Sep 7. Review.

16.

Restricted transgene expression in the brain with cell-type specific neuronal promoters.

Delzor A, Dufour N, Petit F, Guillermier M, Houitte D, Auregan G, Brouillet E, Hantraye P, Déglon N.

Hum Gene Ther Methods. 2012 Aug;23(4):242-54. doi: 10.1089/hgtb.2012.073. Epub 2012 Aug 30.

17.

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW.

Neuron. 2012 Jun 21;74(6):1031-44. doi: 10.1016/j.neuron.2012.05.009.

18.

Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Ehrlich ME.

Neurotherapeutics. 2012 Apr;9(2):270-84. doi: 10.1007/s13311-012-0112-2. Review.

19.

Intercellular (mis)communication in neurodegenerative disease.

Garden GA, La Spada AR.

Neuron. 2012 Mar 8;73(5):886-901. doi: 10.1016/j.neuron.2012.02.017. Review.

20.

Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease.

Lerner RP, Trejo Martinez Ldel C, Zhu C, Chesselet MF, Hickey MA.

Brain Res Bull. 2012 Apr 10;87(6):571-8. doi: 10.1016/j.brainresbull.2012.01.012. Epub 2012 Feb 4.

Items per page

Supplemental Content

Write to the Help Desk